Table 1.
Patient baseline characteristics.
| Characteristic | n = 98 |
|---|---|
| Mean age (SD), years | 43 (12.41) |
| Gender Female, n (%) | 70 (71.43) |
| Type of disease, n (%) | |
| Crohn’s disease | 66 (67.35) |
| Ulcerative colitis | 32 (32.65) |
| Harvey–Bradshaw index, n (%) | |
| Remission (score 0–4) | 53 (54.07) |
| Mild (score 5–7) | 13 (13.26) |
| Moderate (score 8–16) | 0 |
| Severe (score > 16) | 0 |
| Partial Mayo Scoring Index; n (%) | |
| Remission (score 0–1) | 18 (18.36) |
| Mild (score 2–4) | 14 (14.32) |
| Moderate (score 5–6) | 0 |
| Severe (score 7–9) | 0 |
| Previous surgery, n (%) | |
| Yes | 26 (26.53) |
| No | 72 (73.47) |
| Mean CRP (SD), mg/L a | 4.12 (6.16) |
| Mean faecal calprotectin (SD), µg/g b | 333.21 (647.64) |
| Mean Hb (SD), g/dL | 13.44 (1.02) |
| Mean s-ferritin (SD), μg/L | 48.38 (64.60) |
| Mean s-iron (SD), μg/dL | 51.92 (41.03) |
| Mean TSAT (SD), % | 12.78 (4.19) |
| Mean vitamin B12 (SD), pg/mL c | 346.91 (270.79) |
| Mean folic acid (SD), ng/mL d | 7.01 (3.34) |
| Treatment, n (%) | |
| Mesalazine | 31 (31.63) |
| Steroids | 6 (6.12) |
| Thiopurines | 24 (24.49) |
| Methotrexate | 4 (4.08) |
| Anti-TNF | 38 (38.78) |
| Vedolizumab | 6 (6.12) |
| Ustekinumab | 11 (11.22) |
| Apheresis | 2 (2.04) |
CRP = C-reactive protein; SD = standard deviation; s-ferritin = serum ferritin; s-iron = serum iron; TSAT = transferrin saturation index; TNF = tumour necrosis factor; a = Normal CRP value < 5 mg/L; b = Normal faecal calprotectin value < 200 µg/g; c = Normal vitamin B12 range 180–914 pg/mL; d = Normal folic acid range 3–17 ng/mL.